Please assess the completion status of the following clinical trial:

Trial Title: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged ≥18 years~* Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably including the presence of neuroendocrine features by immunohistochemistry~* At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2~* Adequate organ function~Exclusion Criteria:~* Prior chemotherapy for extensive-stage SCLC~* Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.~* Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure~* Known history of stroke or cerebrovascular accident within 6 months prior to enrollment~* Other uncontrolled serious chronic disease or conditions that in the investigator's opinion could affect compliance or follow-up in the protocol~* Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to enrollment or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response)~* Receipt of any investigational medication within 4 weeks prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- trilaciclib + carboplatin/etoposide (Type: EXPERIMENTAL): All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
- trilaciclib/placebo + carboplatin/etoposide (Type: EXPERIMENTAL): All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).